01—Abstract
Summary
Summary of the 10-Q filed April 29, 2024. Cited figures are marked; the original filing is the authoritative source.
Edwards Lifesciences Corporation reported solid revenue growth in the first quarter of 2024, with net sales increasing by 9.5% to $1.6 billiona compared to the prior year.
This growth was primarily driven by strong performance in Transcatheter Aortic Valve Replacement (TAVR) and Transcatheter Mitral and Tricuspid Therapies (TMTT) product lines. The company also incurred significant separation costs related to the planned spin-off of its Critical Care product group, impacting net income. Operationally, the company continues to invest in research and development, essential for its long-term growth strategy in structural heart disease and related therapies.
While the company generated positive operating income, the reported net cash used in operating activities was negative, largely due to a substantial tax deposit made related to a contested tax matter. Investors should monitor the progress of the Critical Care spin-off and the resolution of ongoing tax disputes, which could have future financial implications.
02—Key points
Key Highlights
- Net sales increased by 9.5% to $1.6 billion in Q1 2024 compared to Q1 2023, primarily driven by TAVR and TMTT product sales.
- Transcatheter Mitral and Tricuspid Therapies (TMTT) saw a significant 75.2% increase in net sales, highlighting growth in this emerging area.
- The company incurred $41.3 million in separation costs related to the planned spin-off of its Critical Care product group.
- Diluted Earnings Per Share (EPS) was $0.58, a slight increase from $0.56 in the prior year period.
- Net cash used in operating activities was $(53.5) million, significantly impacted by a $305 million tax deposit for contested tax liabilities.
- The company ended the quarter with $1.22 billion in cash and cash equivalents, indicating a healthy liquidity position.
- The company announced the completion of patient treatment in its PROGRESS pivotal trial for moderate aortic stenosis and received CE Mark approval for its Edwards SAPIEN 3 Ultra RESILIA valve in Europe.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q1 FY2024, Edwards Lifesciences kept $0.26.
- Revenue$1.33B100.0%
- Cost of revenue−$286.9M21.6%
- Gross profit$1.04B78.4%
- Operating costs−$694.0M52.2%
- Operating income$349.0M26.2%
- Interest, other & tax$2.0M0.2%
- Net income$351.0M26.4%
04—Financials
Financial Highlights
Figures from 10-QQ1 FY2024filed April 29, 2024Financial Statements
Q1 FY2024 against Q1 FY2023
| Line item | Q1 FY2024Q1 FY2023 | Change |
|---|---|---|
| Revenue | $1.33B$1.22B | +8.9% |
| Cost of Revenue | $286.90M$329.50M | −12.9% |
| Gross Profit | $1.04B$992.30M | +5.1% |
| R&D Expenses | $256.70M$261.20M | −1.7% |
| SG&A Expenses | $428.40M$436.30M | −1.8% |
| Operating Income | $349.00M$388.40M | −10.1% |
| Net Income | $351.00M$340.50M | +3.1% |
| EPS (Basic) | $0.58$0.56 | +3.6% |
| EPS (Diluted) | $0.58$0.56 | +3.6% |
| Shares Outstanding (Basic) | 601.60M607.50M | −1.0% |
| Shares Outstanding (Diluted) | 604.10M610.90M | −1.1% |
05—Questions
Frequently Asked Questions
What is the primary driver of Edwards Lifesciences' revenue growth in Q1 2024?
The primary driver of revenue growth was the strong performance of its Transcatheter Aortic Valve Replacement (TAVR) products, particularly the Edwards SAPIEN platform, along with significant growth in Transcatheter Mitral and Tricuspid Therapies (TMTT) sales.
What are the significant expenses impacting the company's profitability in this quarter?
The company incurred $41.3 million in separation costs related to the planned spin-off of its Critical Care product group. Additionally, there are ongoing legal and tax-related expenses that require careful monitoring.
What is the status of the company's tax disputes?
Edwards Lifesciences is actively contesting a notice of deficiency from the IRS for tax years 2015-2017, related to transfer pricing. The company made a significant deposit of $305 million in March 2024 to mitigate interest on potential liabilities while preparing for judicial proceedings. Similar disputes may arise for tax years 2018-2023. An assessment of approximately $110 million has also been claimed by the Israel Tax Authority.
How is the planned spin-off of the Critical Care business progressing?
The company announced its intention to spin off the Critical Care product group, expected to be completed near the end of 2024, subject to customary conditions. Significant separation costs of $41.3 million were incurred in Q1 2024 related to this process.
06—Continue